Clinical Trial Detail

NCT ID NCT02036476
Title Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

Merkel cell carcinoma

Therapies

Cabozantinib

Age Groups: adult

No variant requirements are available.